1-3 of 3
Marja-Liisa Karjalainen-Lindsberg
Close
Sort by
Journal Articles

Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients

Clinical Trials & Observations
Kristiina Karihtala, Suvi-Katri Leivonen, Marja-Liisa Karjalainen-Lindsberg, Fong Chun Chan, Christian Steidl, Teijo Pellinen, Sirpa Leppä
Journal: Blood Advances
Blood Adv (2022) 6 (6): 1919–1931.
https://doi.org/10.1182/bloodadvances.2021006189
Published: 2022
Includes: Supplemental data
Journal Articles

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma

Clinical Trials & Observations
Leo Meriranta, Annika Pasanen, Amjad Alkodsi, Jari Haukka, Marja-Liisa Karjalainen-Lindsberg, Sirpa Leppä
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3742–3753.
https://doi.org/10.1182/bloodadvances.2020001727
Published: 2020
Includes: Supplemental data
Journal Articles

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Clinical Trials & Observations
Sirpa Leppä, Judit Jørgensen, Anne Tierens, Leo Meriranta, Ingunn Østlie, Peter de Nully Brown, Unn-Merete Fagerli, Thomas Stauffer Larsen, Susanna Mannisto, Lars Munksgaard, Martin Maisenhölder, Kaija Vasala, Peter Meyer, Mats Jerkeman, Magnus Björkholm, Øystein Fluge, Sirkku Jyrkkiö, Knut Liestøl, Elisabeth Ralfkiaer, Signe Spetalen, Klaus Beiske, Marja-Liisa Karjalainen-Lindsberg, Harald Holte
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1906–1915.
https://doi.org/10.1182/bloodadvances.2020001518
Published: 2020
Includes: Supplemental data